Why Neurocrine Biosciences Stock Sank Today
Despite better-than-expected profitability in the fourth quarter, which it reported late last week, Neurocrine Biosciences (NASDAQ: NBIX) hasn't been wowing analysts lately. On Monday, no less than three of them lowered their price targets on the biotech's shares,
Why Neurocrine Biosciences Inc. (NBIX) Crashed Last Week
We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a look at where Neurocrine Biosciences Inc. (NASDAQ:NBIX) stands against the other stocks.
Neurocrine Biosciences Reports Mixed Q4
Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.
Why Is Neurocrine Biosciences Stock Trading Lower On Friday?
Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth despite near-term challenges.
Neurocrine Biosciences stock falls on revenue miss
Biosciences (NASDAQ: NBIX) tumbled 11% as the company reported revenues that fell short of estimates. Despite reporting a 26% growth in INGREZZA® (valbenazine) net product sales for the full year of 2024 compared to the previous year,
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS is $1 EPS, expectations were $1.62. Operator: Good day, everyone, and welcome to today’s Neurocrine Biosciences Reports Q4 and Fiscal Year 2024 Earnings Call.
FiercePharma15h
With Teva competition heating up, Neurocrine's tame Ingrezza forecast spooks investors
Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...
Neurocrine price target lowered to $163 from $165 at Guggenheim
Guggenheim lowered the firm’s price target on Neurocrine (NBIX) to $163 from $165 and keeps a Buy rating on the shares after the company ...
Mirae Asset Global Investments Co. Ltd. Grows Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 21.8% in the fourth quarter, according to the company in its most ...
UBS cuts Neurocrine Bio. stock target to $154, maintains Buy rating
UBS analyst Ashwani Verma adjusted the price target for Neurocrine Biosciences (NASDAQ:NBIX) to $154 from the previous $176, while continuing to recommend the stock as a Buy. Currently trading at $118 ...
Neurocrine (NBIX) Gets a Buy from Evercore ISI
In a report released on February 7, Cory Kasimov from Evercore ISI maintained a Buy rating on Neurocrine (NBIX – Research Report), with a price ...
Royal Bank of Canada Lowers Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $148.00
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price lowered by Royal Bank of Canada from $154.00 to $148.00 in a report released on Friday,Benzinga reports. The brokerage currently ...
These Stocks Are Moving the Most Today: Amazon, Affirm, Pinterest, Take-Two, Bill Holdings, e.l.f. Beauty, Neurocrine Biosciences, and More
Amazon falls after guidance disappoints and cloud-computing growth misses estimates, Affirm jumps after fiscal second-quarter ...
Neurocrine management to meet with Oppenheimer
Meeting to be held on February 14 hosted by Oppenheimer. Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' ...